Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Sibold William John | President and CEO | Sep 09 '24 | Sale | 243.83 | 6,363 | 1,551,490 | 55,887 | Sep 11 09:51 PM | William John Sibold | Officer | Sep 09 '24 | Proposed Sale | 243.83 | 6,363 | 1,551,514 | | Sep 10 09:29 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jun 14 '24 | Option Exercise | 87.09 | 1,900 | 165,471 | 7,400 | Jun 18 09:39 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jun 14 '24 | Sale | 280.00 | 1,900 | 532,000 | 5,500 | Jun 18 09:39 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jun 12 '24 | Option Exercise | 87.92 | 2,000 | 175,840 | 7,500 | Jun 14 09:44 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Jun 12 '24 | Sale | 285.00 | 2,000 | 570,000 | 5,500 | Jun 14 09:44 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | May 21 '24 | Sale | 231.34 | 1,036 | 239,668 | 5,500 | May 23 09:36 PM | CRAVES FRED B | Director | May 14 '24 | Option Exercise | 103.02 | 22,489 | 2,316,844 | 435,851 | May 16 09:53 PM | CRAVES FRED B | Director | May 14 '24 | Sale | 212.88 | 22,489 | 4,787,404 | 413,362 | May 16 09:53 PM | Taub Rebecca | Pres., R&D, and CMO | Apr 08 '24 | Option Exercise | 9.45 | 2,676 | 25,288 | 461,675 | Apr 10 08:53 PM | Taub Rebecca | Pres., R&D, and CMO | Apr 08 '24 | Sale | 245.99 | 2,676 | 658,258 | 458,999 | Apr 10 08:53 PM | FRIEDMAN PAUL A | Director | Apr 08 '24 | Option Exercise | 9.45 | 26,270 | 248,251 | 212,005 | Apr 10 08:50 PM | FRIEDMAN PAUL A | Director | Apr 08 '24 | Sale | 246.19 | 26,270 | 6,467,491 | 185,735 | Apr 10 08:50 PM | Taub Rebecca | Pres., R&D, and CMO | Apr 03 '24 | Option Exercise | 9.45 | 27,845 | 263,135 | 486,844 | Apr 05 08:50 PM | Taub Rebecca | Pres., R&D, and CMO | Apr 05 '24 | Option Exercise | 9.45 | 27,506 | 259,932 | 486,505 | Apr 05 08:50 PM | Taub Rebecca | Pres., R&D, and CMO | Apr 04 '24 | Option Exercise | 9.45 | 18,537 | 175,175 | 477,536 | Apr 05 08:50 PM | Taub Rebecca | Pres., R&D, and CMO | Apr 03 '24 | Sale | 245.14 | 27,845 | 6,825,976 | 458,999 | Apr 05 08:50 PM | Taub Rebecca | Pres., R&D, and CMO | Apr 05 '24 | Sale | 243.36 | 27,506 | 6,693,790 | 458,999 | Apr 05 08:50 PM | Taub Rebecca | Pres., R&D, and CMO | Apr 04 '24 | Sale | 242.91 | 18,537 | 4,502,823 | 458,999 | Apr 05 08:50 PM | FRIEDMAN PAUL A | Director | Apr 05 '24 | Option Exercise | 9.45 | 27,613 | 260,943 | 213,348 | Apr 05 08:50 PM | FRIEDMAN PAUL A | Director | Apr 03 '24 | Option Exercise | 9.45 | 27,407 | 258,996 | 213,142 | Apr 05 08:50 PM | FRIEDMAN PAUL A | Director | Apr 04 '24 | Option Exercise | 9.45 | 18,710 | 176,810 | 204,445 | Apr 05 08:50 PM | FRIEDMAN PAUL A | Director | Apr 05 '24 | Sale | 243.40 | 27,613 | 6,721,081 | 185,735 | Apr 05 08:50 PM | FRIEDMAN PAUL A | Director | Apr 03 '24 | Sale | 245.12 | 27,407 | 6,718,002 | 185,735 | Apr 05 08:50 PM | FRIEDMAN PAUL A | Director | Apr 04 '24 | Sale | 242.96 | 18,710 | 4,545,721 | 185,735 | Apr 05 08:50 PM | Levy Richard S | Director | Apr 01 '24 | Option Exercise | 63.92 | 11,000 | 703,160 | 21,298 | Apr 03 08:47 PM | Levy Richard S | Director | Apr 01 '24 | Sale | 257.48 | 11,000 | 2,832,335 | 10,298 | Apr 03 08:47 PM | BATE KENNETH | Director | Apr 01 '24 | Option Exercise | 57.96 | 21,277 | 1,233,187 | 22,475 | Apr 03 08:44 PM | BATE KENNETH | Director | Apr 02 '24 | Option Exercise | 105.08 | 11,212 | 1,178,157 | 12,410 | Apr 03 08:44 PM | BATE KENNETH | Director | Apr 01 '24 | Sale | 257.26 | 21,277 | 5,473,779 | 1,198 | Apr 03 08:44 PM | BATE KENNETH | Director | Apr 02 '24 | Sale | 244.49 | 11,212 | 2,741,219 | 1,198 | Apr 03 08:44 PM | Daly James M | Director | Apr 01 '24 | Option Exercise | 100.79 | 21,577 | 2,174,711 | 22,775 | Apr 03 08:41 PM | Daly James M | Director | Apr 02 '24 | Option Exercise | 105.08 | 10,912 | 1,146,633 | 12,110 | Apr 03 08:41 PM | Daly James M | Director | Apr 01 '24 | Sale | 257.24 | 21,577 | 5,550,544 | 1,198 | Apr 03 08:41 PM | Daly James M | Director | Apr 02 '24 | Sale | 244.51 | 10,912 | 2,668,087 | 1,198 | Apr 03 08:41 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 14 '23 | Option Exercise | 87.92 | 2,000 | 175,840 | 7,667 | Dec 18 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 15 '23 | Option Exercise | 87.92 | 2,000 | 175,840 | 7,667 | Dec 18 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 15 '23 | Sale | 238.50 | 2,000 | 477,000 | 5,667 | Dec 18 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 14 '23 | Sale | 232.50 | 2,000 | 465,000 | 5,667 | Dec 18 04:30 PM | BAKER BROS. ADVISORS LP | Director | Dec 13 '23 | Buy | 219.39 | 81,159 | 17,805,684 | 1,774,294 | Dec 14 06:10 PM | BAKER BROS. ADVISORS LP | Director | Dec 14 '23 | Buy | 228.32 | 20,633 | 4,710,893 | 1,793,403 | Dec 14 06:10 PM | BAKER BROS. ADVISORS LP | Director | Dec 12 '23 | Buy | 218.31 | 34,578 | 7,548,616 | 1,699,129 | Dec 14 06:09 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 13 '23 | Option Exercise | 87.92 | 2,500 | 219,800 | 8,167 | Dec 14 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 12 '23 | Option Exercise | 87.92 | 1,300 | 114,296 | 6,967 | Dec 14 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 13 '23 | Sale | 225.40 | 2,500 | 563,500 | 5,667 | Dec 14 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 12 '23 | Sale | 217.85 | 1,300 | 283,200 | 5,667 | Dec 14 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Dec 04 '23 | Option Exercise | 81.16 | 1,800 | 146,090 | 16,801 | Dec 06 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Dec 05 '23 | Option Exercise | 87.09 | 1,000 | 87,090 | 16,001 | Dec 06 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Dec 04 '23 | Sale | 218.87 | 1,800 | 393,964 | 15,001 | Dec 06 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Dec 05 '23 | Sale | 227.33 | 1,000 | 227,330 | 15,001 | Dec 06 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Nov 29 '23 | Option Exercise | 73.75 | 4,000 | 295,000 | 19,001 | Dec 01 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Nov 30 '23 | Option Exercise | 73.75 | 3,000 | 221,250 | 18,001 | Dec 01 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Nov 29 '23 | Sale | 199.19 | 4,000 | 796,750 | 15,001 | Dec 01 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Nov 30 '23 | Sale | 204.58 | 3,000 | 613,730 | 15,001 | Dec 01 04:30 PM | BAKER BROS. ADVISORS LP | Director | Nov 21 '23 | Buy | 188.47 | 64,350 | 12,128,340 | 1,667,104 | Nov 21 06:15 PM | BAKER BROS. ADVISORS LP | Director | Nov 17 '23 | Buy | 174.70 | 46,370 | 8,100,704 | 1,588,541 | Nov 21 06:14 PM | BAKER BROS. ADVISORS LP | Director | Nov 20 '23 | Buy | 185.74 | 20,709 | 3,846,575 | 1,607,668 | Nov 21 06:14 PM | BAKER BROS. ADVISORS LP | Director | Nov 14 '23 | Buy | 156.42 | 34,188 | 5,347,837 | 1,531,757 | Nov 15 05:13 PM | BAKER BROS. ADVISORS LP | Director | Nov 15 '23 | Buy | 161.97 | 15,199 | 2,461,721 | 1,545,775 | Nov 15 05:13 PM | BAKER BROS. ADVISORS LP | Director | Nov 13 '23 | Buy | 143.21 | 69,839 | 10,001,368 | 1,465,494 | Nov 15 05:12 PM | BAKER BROS. ADVISORS LP | Director | Nov 14 '23 | Buy | 154.00 | 37,660 | 5,799,653 | 1,500,227 | Nov 15 05:12 PM |
|